AstraZeneca PLC (AZN)vsImpact BioMedical, Inc. (IBO)
AZN
AstraZeneca PLC
$187.37
+1.17%
HEALTHCARE · Cap: $287.11B
IBO
Impact BioMedical, Inc.
$0.66
-2.59%
HEALTHCARE · Cap: $71.16M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 183559272% more annual revenue ($58.74B vs $32,000). AZN leads profitability with a 17.4% profit margin vs 0.0%. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
IBO
Avoid15
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+4.1%
Fair Value
$214.51
Current Price
$187.37
$27.14 discount
Intrinsic value data unavailable for IBO.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Earnings expanding 53.9% YoY
Every $100 of equity generates 23 in profit
Strong operational efficiency at 21.6%
Generating 1.4B in free cash flow
Conservative balance sheet, low leverage
Areas to Watch
Expensive relative to growth rate
Moderate valuation
4.1% revenue growth
Distress zone — elevated risk
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.
Bull Case : IBO
The strongest argument for IBO centers on Debt/Equity.
Bear Case : AZN
The primary concerns for AZN are PEG Ratio, P/E Ratio, Revenue Growth.
Bear Case : IBO
The primary concerns for IBO are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
AZN is growing revenue faster at 4.1% — sustainability is the question.
AZN generates stronger free cash flow (1.4B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
AZN scores higher overall (64/100 vs 15/100), backed by strong 17.4% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Impact BioMedical, Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Impact BioMedical, Inc. is a forward-thinking biotechnology firm dedicated to the development of pioneering therapeutics and technologies that tackle pressing healthcare issues. The company employs cutting-edge research and development methodologies to enhance patient health outcomes and elevate quality of life. With a strong intellectual property portfolio and a focus on scientific excellence, Impact BioMedical is strategically positioned for significant growth in the dynamic healthcare landscape. Its diverse product pipeline and strategic partnerships present promising opportunities for institutional investors seeking to invest in the transformative advancements of the biopharmaceutical sector.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?